Clinical Trials

A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell and Follicular B-Cell Non-Hodgkin Lymphoma


Study ID
Corvus Pharma-CPI-818-001

NCT Number
NCT03952078 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0101

Principle Investigator
Dr. Tatyana Feldman

Phase
I/II

Sponsor
Corvus Pharmaceuticals


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now